Articles On Cyclopharm (ASX:CYC)

Cyclopharm (ASX:CYC) shares are down by more than 40 per cent in early trading after the US Food and Drug Administration declined to immediately approve its nuclear lung imaging agent, Technegas. The FDA issued what’s known as a complete re...

Cyclopharm Limited (ASX: CYC) shares are taking an absolute pummelling today. At the time of writing, the Cyclopharm share price is crashing 41.61% lower to $1.60. Below, we take a look at the ASX healthcare company’s latest market update....

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

The diagnostics imaging industry has come a long way since the days of X-rays and CT scans – two technologies that have been around for decades. Although they have not been replaced entirely, a breed of new ASX small caps have emerged over...

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

For all the leaps and bounds in medical science, the know-how behind detecting diseases hasn’t changed much in decades – or even centuries. Take X-rays, which are widely used despite the wee problem of irradiating the patients. And that’s b...

The Cyclopharm Limited (ASX: CYC) share price is dipping today after the company released its 2021 AGM Presentation. Cyclopharm shares are down 1% to $2.82 at the time of writing, after gaining more than 10% over the past week. Cyclopharm...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Inflammatory diseases company Pharmaxis (ASX:PSX) this month welcomed a familiar biotech name to the register: Karst Peak Capital. The Hong Kong and Sydney based ‘contrarian’ fund manager is also a major holder in Neuren and Cyclopharm, and...

What’s the difference between a wind tunnel and a set of lungs? For mechanical engineer Andreas Fouras, the answer is not much. His dabbling in the wind tunnel laboratories at Melbourne’s Monash University made him realise there must be a b...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Summary Radiopharmaceutical company Cyclopharm completed A$30 million placement with overwhelming support from its institutional and sophisticated investors. The Company is well-positioned for the rapid commercialisation in the US, aft...

ASX-listed diagnostic imaging business Cyclopharm is seeking a capital injection to fund its rollout in the United States. 

The Cyclopharm Limited (ASX: CYC) share price was sent soaring today after the company announced a business update. Cyclopharm shares went as high as 14.41% in afternoon trade before closing 6.78% up at $2.52 per share. What Cyclopharm doe...

The Cyclopharm Limited (ASX: CYC) share price continues to bask in the glory of its clinical trial announcement released earlier this week. Shares in the diagnostic imaging technology developer surged 28.2% to a record high of $2.50 in the...

09 Sep 2020 - Cyclopharm (ASX:CYC) today announced a new research collaboration with McMasters University and other industry leaders aimed at understanding the short- term and long…

Fresh off its first sale in the US and positive results from a John Hopkins School of Medicine study, LBT Innovations (ASX:LBT) shares are set to rise again following a European marketing deal. The Adelaide company makes automated microbiol...

Can you tell whether a person has COVID-19 by their cough? Research says it’s highly unlikely you, or even a professional, can accurately identify the origin of wheezes, hems and heaves, and whether it’s the flu or just a drink that’s gone...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Markets be...

The Cyclopharm Limited (ASX: CYC) share price has rocketed out of the gates this morning after the company announced another milestone in its quest to gain approval in the lucrative US market. After jumping as much as 21.83% higher in earl...

14 Apr 2020 - Cyclopharm (ASX:CYC) is pleased to announce that the United States Food and Drug Administration (USFDA) has granted the Company a full application fee waiver of USD $…

Australian company Cyclopharm (ASX:CYC) has announced that the US FDA has granted it a full application fee waiver of US$2.9m related to its recently submitted New Drug Application for Technegas.

Yesterday, Stockhead reviewed the small caps that are devising treatments to fight cancer. There are also a handful of small caps that are seeking to help with diagnostics. In other words these small caps are either seeking to identify the...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Cyclopharm Limited (ASX: CYC) provides an update on progressing its strategy during FY19, which  includes expectations for its full year results and advancement of certain operational matters, including acquiring United States Food and Drug...

Air pollution is a growing problem that in recent days has reached our own backyard. Because of the bushfires in surrounding areas, Sydney’s air has been ranked the ninth worst in the world. It’s not the first time in history it’s happened...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

In the Australian health care system, three levels of government are responsible for providing universal health care- federal government, state and territory government and local government. Funding and indirect support are provided by the...

For a certain generation of investors the word ‘laser’ is indelibly tied to a Dr Evil reference. Over the last two years Invion (ASX:IVX) has been valiantly working against this association, and today says its lasers (not attached to the he...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

The TechKnow Invest Roadshow provides retail and institutional investors, as well as brokers, an opportunity to learn more about a range of tech and biotech companies. More than 20 companies will present at the conference on Thursday, Octob...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

Radiopharmaceutical company Cyclopharm (ASX: CYC) has announced four management appointments.

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...

International research suggests shares in companies that buy in their own equities are more likely to respond positively through share price appreciation. Investors should note, however, buying back own stock is not a guarantee of significa...